A systematic review of the literature on economic evaluations that compared candesartan and losartan treatments in the treatment of hypertension in Europe and budget impact of the increase of the candesartan market shares on the Spanish National Health System. The identified studies indicated that candesartan might involve medical cost savings compared to losartan. Additionally, greater market shares of candesartan would also involve potential cost savings for the Spanish National Health System.
